Viral kinetics during rescue treatment with intravenous silibinin in a patient with chronic hepatitis C genotype 4– A case report

Introduction: About 50% of patients with hepatitis C genotype 1 and 4 achieve a sustained virological response (SVR) under a therapy with PEG-Interferon and Ribavirin. Recently released, more efficient regimens with protease inhibitors are not indicated in genotype 4 Hepatitis C. Intravenous Silibinin (ivSIL) has been shown to be effective as rescue treatment for nonresponders to the current standard of care. Silibinin is an extract that is derived from the seeds of the milkthistle and has been shown to be a potent agent against the hepatitis C virus. We present the case of a 28-year-old female patient with HCV…